Is HCG an approved drug or a research compound?

HCG is an FDA-approved pharmaceutical with three labeled indications: prepubertal cryptorchidism, male hypogonadotropic hypogonadism, and female ovulation induction/ART. Brand names include Pregnyl, Novarel, and Ovidrel (recombinant). It is also used off-label for TRT co-administration and post-cycle therapy, for which it is not approved. Research-grade HCG sold online is unregulated and not the same as pharmaceutical-grade product.

Why is HCG prohibited by WADA?

HCG is prohibited in male athletes at all times under the WADA S2 Prohibited List (Peptide Hormones, Growth Factors). Because it stimulates Leydig cells to produce endogenous testosterone, it can be used to circumvent testosterone limits or accelerate recovery after AAS use. Female athletes are exempt (HCG is naturally produced in pregnancy). The default sanction for a positive HCG test in male sport is four years.

What is HCG's half-life and how does it differ from LH?

HCG has a terminal half-life of approximately 29–38 hours after injection, compared to LH's ~25-30 minutes. Both molecules act at the same LHCGR receptor, but HCG's unique 24-amino-acid C-terminal extension — carrying four sialic-acid-rich O-linked glycosylation sites — blocks hepatic clearance. This pharmacokinetic difference is why a single HCG injection produces a sustained testosterone stimulus lasting several days.

How is HCG used to preserve fertility during TRT?

Exogenous testosterone suppresses the HPG axis, reducing intratesticular testosterone by ~94% and causing testicular atrophy and azoospermia over time. Co-administering HCG at approximately 500 IU subcutaneously every other day maintains Leydig cell stimulation and prevents this suppression. A controlled cohort study found no azoospermia at this dose in men on TRT. This is off-label use and should be managed by a qualified clinician.

What are the main risks of HCG use?

In women, OHSS is the most serious risk: severe cases involve massive fluid shifts, thromboembolism, and hospitalization (0.1–2% of ART cycles). In men, gynecomastia is the most common concern (~10–20%), driven by aromatization of testosterone to estradiol; aromatase inhibitors can mitigate this. Repeated use can induce anti-HCG antibodies (especially with urinary-derived preparations). Off-label and research-grade HCG carries the added risk of unregulated product quality.

Does HCG work for weight loss?

No. The FDA has explicitly warned that HCG has no proven benefit for weight loss and that claims on HCG diet products are fraudulent. Weight loss attributed to HCG diet protocols is a result of severe caloric restriction, not the HCG itself.

Hormonal

HCG

Also known as: Human Chorionic Gonadotropin, hCG, Choriogonadotropin, Pregnyl, Novarel, Ovidrel, Chorionic Gonadotropin

A glycoprotein gonadotropin that acts as an LH-receptor agonist; FDA-approved for hypogonadism, cryptorchidism, and ovulation induction, though often encountered in research or...

Last updated July 16, 2026

Reconstitute this peptide Buy HCG

Overview

Human chorionic gonadotropin (HCG) is a 37 kDa glycoprotein consisting of a non-covalently bound alpha and beta subunit. The alpha subunit is shared with FSH, LH, and TSH; the beta subunit is HCG-specific and carries a unique 24-amino-acid C-terminal extension rich in O-linked sialic acid, which accounts for its dramatically extended half-life (~36 hours) compared to LH (~25-30 minutes). HCG binds the same receptor as LH (LHCGR), a G-protein-coupled receptor expressed on Leydig cells in the testes and on granulosa and luteal cells in the ovaries. In males, it drives intratesticular testosterone production via the StAR-CYP11A1 steroidogenic pathway; in females, it sustains corpus luteum progesterone secretion and is the signal of early pregnancy. These pharmacological properties are the basis for three FDA-approved clinical indications: prepubertal cryptorchidism, male hypogonadotropic hypogonadism, and ovulation induction or ART triggering in women. Beyond FDA-labeled uses, HCG is widely used off-label in men undergoing testosterone replacement therapy (TRT) to preserve intratesticular testosterone and spermatogenesis, and in post-cycle therapy (PCT) after anabolic steroid use. Evidence for TRT co-administration is moderate (cohort studies); evidence for PCT efficacy is anecdotal with no RCTs. WADA prohibits HCG in male athletes at all times under the S2 Prohibited List category (Peptide Hormones, Growth Factors). This entry is for research and educational reference only.

How it works

HCG acts as a full agonist at the LH/choriogonadotropin receptor (LHCGR), a Gs protein-coupled receptor. Receptor activation drives adenylyl cyclase, increases intracellular cAMP, and activates PKA, which phosphorylates the steroidogenic acute regulatory protein (StAR). StAR facilitates cholesterol import into the mitochondrial inner membrane, where CYP11A1 converts it to pregnenolone — the committed step toward testosterone biosynthesis in Leydig cells. In females, the same cascade sustains the corpus luteum, maintaining progesterone output and preventing luteolysis. HCG's prolonged half-life relative to LH is structurally explained by the sialic-acid-rich C-terminal peptide on the beta subunit, which blocks hepatic asialoglycoprotein receptor clearance; enzymatic removal of sialic acid collapses HCG half-life to ~5.7 minutes.

Researched effects

Clinical Restores and maintains intratesticular testosterone in male hypogonadotropic hypogonadism
Clinical Induces testicular descent in a proportion of boys with prepubertal cryptorchidism (~25%)
Clinical Triggers final oocyte maturation as an LH surrogate in IVF/ART protocols
Clinical Preserves spermatogenesis and prevents azoospermia when co-administered with TRT
Anecdotal Accelerates HPG-axis recovery and sperm count normalization after anabolic steroid use (PCT context)
Clinical Increases testicular volume and serum testosterone in men with secondary hypogonadism

Evidence levels: Clinical (human trials) · Preclinical (animal/lab) · Anecdotal (community-reported).

Dosing reference

For research reference only — not a recommendation.

Clinical / studied dosing

HCG is dosed in International Units (IU) and its use is indication-specific. For male hypogonadotropic hypogonadism and spermatogenesis induction: 4,000 IU IM three times per week for 6–9 months, then 2,000 IU three times per week; short-course induction regimens use 500–1,000 IU IM three times per week for 3 weeks, then twice weekly for 3 weeks. For TRT co-administration (off-label, fertility preservation): 500 IU SC every other day — this dose was shown in a cohort study to fully prevent the ~94% drop in intratesticular testosterone caused by exogenous testosterone alone. For female ART/IVF ovulation triggering: single dose 5,000–10,000 IU IM (or recombinant choriogonadotropin alfa 250 mcg SC as the Ovidrel equivalent). For cryptorchidism: 500–5,000 IU IM in various protocols (e.g., 3 times weekly for 3 weeks). These are FDA-labeled or well-documented off-label clinical doses; they are not recommendations.

Community-reported dosing (anecdotal)

Anecdotal and research-reference only; not medical advice. Outside clinical fertility/hypogonadism settings, HCG is discussed in fitness and TRT communities primarily in two roles. (1) TRT co-use: 250–500 IU SC two to three times per week to maintain testicular size and intratesticular testosterone while on exogenous testosterone — the 500 IU every-other-day dose closely mirrors the evidence-based TRT co-administration protocol above. (2) PCT: 500–1,000 IU every other day or daily for 10–14 days immediately after an anabolic steroid cycle to stimulate endogenous testosterone recovery, often followed by a SERM. No RCT data support PCT efficacy. Product quality and sterility of non-pharmaceutical HCG are real risks. HCG is WADA-prohibited in male athletes at all times.

Half-life: The intact HCG dimer has a terminal elimination half-life of approximately 29–38 hours after subcutaneous or intramuscular administration (pharmacokinetic studies: ~36–38 h in most assessments). Elimination is biphasic: initial phase ~4–6 hours (distribution), terminal phase ~29–38 hours. This markedly exceeds endogenous LH (~25–30 minutes), owing to the sialic-acid-protected C-terminal extension on the beta subunit. The free beta-subunit has an intermediate half-life of ~23 hours. Human data from controlled PK studies.
Routes: subcutaneous, intramuscular

Safety & side effects

HCG is a well-characterized pharmaceutical with decades of clinical use, but several risks apply. In women, OHSS (ovarian hyperstimulation syndrome) is the primary serious concern: HCG drives VEGF-mediated vascular permeability, causing fluid shifts; moderate OHSS occurs in 3–7% of stimulation cycles, severe OHSS in 0.1–2%. Risk factors include PCOS, high antral follicle count, and estradiol >3,000 pg/mL. In high-risk cases, a GnRH agonist trigger is preferred. In men, the major risk is gynecomastia (~10–20% of users) due to aromatization of excess testosterone to estradiol; aromatase inhibitors are used to manage this. Anti-HCG antibodies can form with repeated urinary-derived HCG administration; recombinant preparations have lower immunogenicity. Repeated supraphysiological stimulation may also desensitize Leydig cell LHCGR. The FDA has issued explicit warnings against off-label use of HCG for weight loss, which lacks evidence. WADA prohibits HCG in male athletes at all times under S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics); the default sanction is a 4-year ban; female athletes during pregnancy are exempt. Non-pharmaceutical HCG (unregulated research-grade) carries product-quality and sterility risks. This information is for research and educational reference only.

Research summary

HCG has a mature clinical evidence base by peptide-compound standards — it has been in therapeutic use since the 1930s–1940s and is FDA-approved for three distinct indications. Evidence for male hypogonadotropic hypogonadism and ART ovulation triggering is robust, underpinned by decades of RCTs and real-world data. The TRT co-administration literature (specifically preserving intratesticular testosterone at 500 IU every-other-day) is compelling from controlled cohort studies, including data showing zero azoospermia at this dose vs. near-total suppression on testosterone alone. Cryptorchidism evidence is moderate: descent is achieved in ~25% of cases, not much better than GnRH agonist alternatives. The PCT (post-cycle therapy) context is where evidence is weakest: community use is widespread and theoretically coherent (HCG stimulates Leydig cells during HPG suppression), but no RCT has validated an HPG-recovery benefit over watchful waiting or compared PCT regimens head-to-head in a blinded fashion. OHSS risk in high-responder women is the most clinically significant safety concern, and the shift toward GnRH agonist triggers in IVF is evidence-driven risk reduction. The WADA prohibition reflects the compound's genuine capacity to elevate endogenous testosterone, making it a meaningful performance-enhancement risk in male sport.

FAQ

Is HCG an approved drug or a research compound?: HCG is an FDA-approved pharmaceutical with three labeled indications: prepubertal cryptorchidism, male hypogonadotropic hypogonadism, and female ovulation induction/ART. Brand names include Pregnyl, Novarel, and Ovidrel (recombinant). It is also used off-label for TRT co-administration and post-cycle therapy, for which it is not approved. Research-grade HCG sold online is unregulated and not the same as pharmaceutical-grade product.
Why is HCG prohibited by WADA?: HCG is prohibited in male athletes at all times under the WADA S2 Prohibited List (Peptide Hormones, Growth Factors). Because it stimulates Leydig cells to produce endogenous testosterone, it can be used to circumvent testosterone limits or accelerate recovery after AAS use. Female athletes are exempt (HCG is naturally produced in pregnancy). The default sanction for a positive HCG test in male sport is four years.
What is HCG's half-life and how does it differ from LH?: HCG has a terminal half-life of approximately 29–38 hours after injection, compared to LH's ~25-30 minutes. Both molecules act at the same LHCGR receptor, but HCG's unique 24-amino-acid C-terminal extension — carrying four sialic-acid-rich O-linked glycosylation sites — blocks hepatic clearance. This pharmacokinetic difference is why a single HCG injection produces a sustained testosterone stimulus lasting several days.
How is HCG used to preserve fertility during TRT?: Exogenous testosterone suppresses the HPG axis, reducing intratesticular testosterone by ~94% and causing testicular atrophy and azoospermia over time. Co-administering HCG at approximately 500 IU subcutaneously every other day maintains Leydig cell stimulation and prevents this suppression. A controlled cohort study found no azoospermia at this dose in men on TRT. This is off-label use and should be managed by a qualified clinician.
What are the main risks of HCG use?: In women, OHSS is the most serious risk: severe cases involve massive fluid shifts, thromboembolism, and hospitalization (0.1–2% of ART cycles). In men, gynecomastia is the most common concern (~10–20%), driven by aromatization of testosterone to estradiol; aromatase inhibitors can mitigate this. Repeated use can induce anti-HCG antibodies (especially with urinary-derived preparations). Off-label and research-grade HCG carries the added risk of unregulated product quality.
Does HCG work for weight loss?: No. The FDA has explicitly warned that HCG has no proven benefit for weight loss and that claims on HCG diet products are fraudulent. Weight loss attributed to HCG diet protocols is a result of severe caloric restriction, not the HCG itself.

References

All content is for research and educational use only and is not medical advice. Products are sold for laboratory research only and are not for human consumption.